Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Income from Continuing Operations (2024 - 2026)

Maze Therapeutics' Income from Continuing Operations history spans 3 years, with the latest figure at 24208000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 26.16% to 24208000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 122542000.0, a 336.18% decrease, with the full-year FY2025 number at 131120000.0, down 351.17% from a year prior.
  • Income from Continuing Operations hit 24208000.0 in Q1 2026 for Maze Therapeutics, up from 34568000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for MAZE hit a ceiling of 139056000.0 in Q2 2024 and a floor of 34568000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 10932222.22 across 3 years, with a median of 29654000.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 124.22% in 2025 and later increased 26.16% in 2026.
  • Tracing MAZE's Income from Continuing Operations over 3 years: stood at 29654000.0 in 2024, then decreased by 16.57% to 34568000.0 in 2025, then rose by 29.97% to 24208000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for MAZE at 24208000.0 in Q1 2026, 34568000.0 in Q4 2025, and 30087000.0 in Q3 2025.